Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism.

@article{Fiskerstrand2010MutationsIA,
  title={Mutations in ABHD12 cause the neurodegenerative disease PHARC: An inborn error of endocannabinoid metabolism.},
  author={Torunn Fiskerstrand and Dorra H'mida-Ben Brahim and Stefan Johansson and Abderrahim M'zahem and Bj{\o}rn Ivar Haukanes and Nathalie Drouot and Julian Zimmermann and Andrew J. Cole and Christian A Vedeler and Cecilie Bredrup and Mirna Assoum and M{\'e}riem Tazir and Thomas Klockgether and Abdelmadjid Hamri and Vidar M. Steen and Helge Boman and Laurence A. Bindoff and Michel Koenig and Per Morten Knappskog},
  journal={American journal of human genetics},
  year={2010},
  volume={87 3},
  pages={
          410-7
        }
}

Figures and Tables from this paper

Functional validation of ABHD12 mutations in the neurodegenerative disease PHARC

Two Novel Mutations in ABHD12: Expansion of the Mutation Spectrum in PHARC and Assessment of Their Functional Effects

TLDR
This is the first report of compound heterozygosity in PHARC and the first study to describe how a mutation might affect ABHD12 expression and function.

Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataracts (PHARC) screening in an Italian population

TLDR
To search for PHARC mutations in a cohort of 93 unclassified ataxic patients, 15 patients were selected according to the following criteria: possible recessive inheritance and Refsum-like phenotype (ataxia, visual impairment, neuropathy and hearing loss), the first PHARC screening after the original description of the disorder.

A complex homozygous mutation in ABHD12 responsible for PHARC syndrome discovered with NGS and review of the literature

TLDR
A new complex homozygous mutation c.379_385delAACTACTinsGATTCCTTATATACCATTGTAGTCTTACTGCTTTTGGTGAACACA (p.Asn127Aspfs*23) is detected in a 36‐year‐old man, which suggests that the involvement of ABHD12 in polyneuropathies is possibly underestimated.

ABHD12 controls brain lysophosphatidylserine pathways that are deregulated in a murine model of the neurodegenerative disease PHARC

TLDR
Untargeted metabolomics combined with a genetic mouse model is used to determine that the poorly characterized serine hydrolase α/β-hydrolase domain-containing (ABHD)12, mutations in which cause the human neurodegenerative disorder PHARC, is a principal LPS lipase in the mammalian brain.

Genetic screening for SACS, ABHD12 and PRICKLE1 mutations in ataxia patients from Southern Italy

TLDR
The results confirm the worldwide diffusion, the uniform clinical presentation of the disease and the prevalence of loss of function mutations, further confirming the value of genetic screening for SACS mutation in case of early onset spastic ataxia.

Genotype‐phenotype correlation in a novel ABHD12 mutation underlying PHARC syndrome

TLDR
The genotype‐phenotype correlation of two siblings with a novel genotype underlying PHARC syndrome is described, which highlights the importance of an interdisciplinary diagnostic workup with clinical and molecular genetic testing to avoid a misdiagnosis as Charcot‐Marie‐Tooth disease or Refsum disease.

Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets

TLDR
Based on results obtained in studies conducted in murine models and information derived from analyses in post-mortem tissue samples from patients, the blockade of CB1 receptors has been proposed for acutely modulating motor incoordination in cerebellar ataxias, whereas their chronic activation has be proposed for preserving specific neuronal losses.
...

References

SHOWING 1-10 OF 27 REFERENCES

A novel Refsum-like disorder that maps to chromosome 20

TLDR
Clinical and genetic characterization of a neurologic disorder resembling Refsum disease in a Norwegian consanguineous family and the findings show that the clinical syndromes that include RefSum disease are more heterogeneous than previously recognized.

Recent Advances in the Genetics of Mitochondrial Encephalopathies

TLDR
Most of the genes associated with mitochondrial disease with variable neuropathology have been identified via homozygosity mapping or linkage analysis; however, advances in sequencing technology indicate that the future of genetic diagnosis and disease gene discovery likely lies in high-throughput sequencing.

Mitochondrial Ataxias

  • J. Finsterer
  • Medicine
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 2009
Mitochondrial disorders (MIDs) are an increasingly recognized condition. The second most frequently affected organ in MIDs is the central nervous system. One of the most prevalent clinical CNS

Docosahexaenoic acid attenuates microglial activation and delays early retinal degeneration

TLDR
It is concluded that retinal DHA levels control the activity of microglia and thereby may affect the progression and extent of retinal degeneration.

Biology of endocannabinoid synthesis system.

  • Jun WangN. Ueda
  • Biology, Chemistry
    Prostaglandins & other lipid mediators
  • 2009

Monoacylglycerol Lipase Limits the Duration of Endocannabinoid-Mediated Depolarization-Induced Suppression of Excitation in Autaptic Hippocampal Neurons

TLDR
Strong pharmacological and anatomical evidence is provided that MGL regulates DSE in autaptic hippocampal neurons and, taken together with other studies, emphasizes that endocannabinoid signaling is terminated in temporally diverse ways.

Peroxisomes, Refsum's disease and the α- and ω-oxidation of phytanic acid

TLDR
The current state of knowledge regarding the enzymology of the phytanic acid α-oxidation pathway is described, especially since pharmacological up-regulation of this pathway may form the basis of a new treatment strategy for ARD (adult Refsum9s disease).

Peroxisomes, Refsum's disease and the alpha- and omega-oxidation of phytanic acid.

Targeting the endocannabinoid system: to enhance or reduce?

  • V. Marzo
  • Medicine, Biology
    Nature Reviews Drug Discovery
  • 2008
TLDR
The discovery of compounds that either prolong the lifespan of endocannabinoids or tone down their action for the potential future treatment of pain, affective and neurodegenerative disorders, gastrointestinal inflammation, obesity and metabolic dysfunctions, cardiovascular conditions and liver diseases is discovered.